A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type pSoriaSis (LIMMITLESS)

Trial Profile

A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type pSoriaSis (LIMMITLESS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms LIMMITLESS
  • Sponsors AbbVie
  • Most Recent Events

    • 31 Jul 2017 Planned number of patients changed from 1900 to 2000.
    • 28 Jun 2017 Planned primary completion date changed from 10 Nov 2021 to 30 Nov 2021.
    • 13 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top